Campbell & CO Investment Adviser LLC Sells 6,789 Shares of Amgen Inc. $AMGN

Key Points

• Campbell & CO Investment Adviser LLC reduced its stake in Amgen Inc. by 32.9%, selling 6,789 shares and now holds 13,861 shares valued at approximately $4.32 million.
• Wall Street analysts have varying ratings for Amgen, with one Strong Buy rating, seven Buy ratings, eleven Holds, and two Sell ratings, averaging a consensus target price of $303.76.
• Amgen announced a quarterly dividend of $2.38 per share, which reflects an annualized dividend yield of 3.2%.

Campbell & CO Investment Adviser LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 32.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,861 shares of the medical research company's stock after selling 6,789 shares during the quarter. Campbell & CO Investment Adviser LLC's holdings in Amgen were worth $4,318,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Brighton Jones LLC boosted its stake in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Forum Financial Management LP boosted its stake in Amgen by 0.7% during the 4th quarter. Forum Financial Management LP now owns 352,784 shares of the medical research company's stock valued at $91,950,000 after purchasing an additional 2,411 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its stake in Amgen by 12.9% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 36,971 shares of the medical research company's stock valued at $9,636,000 after purchasing an additional 4,232 shares in the last quarter. Integrated Wealth Concepts LLC boosted its stake in Amgen by 3.4% during the 4th quarter. Integrated Wealth Concepts LLC now owns 23,256 shares of the medical research company's stock valued at $6,061,000 after purchasing an additional 765 shares in the last quarter. Finally, Nebula Research & Development LLC bought a new position in Amgen during the 4th quarter valued at $1,181,000. 76.50% of the stock is owned by institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president owned 8,162 shares of the company's stock, valued at $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.76% of the company's stock.

Amgen Stock Up 0.3%

Shares of NASDAQ:AMGN traded up $0.99 during midday trading on Friday, hitting $286.60. 399,160 shares of the stock were exchanged, compared to its average volume of 2,798,723. The company has a market capitalization of $154.29 billion, a PE ratio of 23.45, a P/E/G ratio of 2.48 and a beta of 0.49. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $339.17. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The business's fifty day simple moving average is $293.16 and its two-hundred day simple moving average is $292.98.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the previous year, the company posted $4.97 earnings per share. The business's quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be paid a $2.38 dividend. The ex-dividend date is Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.3%. Amgen's payout ratio is 77.84%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Bank of America raised their price objective on Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a research note on Wednesday, July 23rd. Morgan Stanley raised their price objective on Amgen from $330.00 to $333.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Cantor Fitzgerald reissued a "neutral" rating and set a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. Finally, Piper Sandler raised their price objective on Amgen from $328.00 to $342.00 and gave the stock an "overweight" rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Amgen currently has an average rating of "Hold" and an average target price of $304.43.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.